Propanc Biopharma, Inc.
PPCB· Nasdaq
PPCBPropanc Biopharma, Inc.
Filed May 14, 2021 · 10-Q · 44 days after period end · 0001493152-21-011560
| Metric | Q3 2021 | Q3 2020 | Q3 2019 | Q3 2018 |
|---|---|---|---|---|
| Net Income | -$417.74K | -$2.59M | -$581.86K | -$1.49M |
| EPS Diluted | -$0.12 | -$348.75 | -$0.89 | -$0.06 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Propanc Biopharma, Inc. · CIK 1517681 · Engraved from SEC EDGAR
ended Mar 31, 2021 · filed May 14, 2021 · 44 d after period end
